India’s MedTech Localization Push: Market Entry Opportunities for Medical Device Manufacturers and Investors

India’s MedTech localization push is opening opportunities for manufacturers, component suppliers, healthcare technology firms, and foreign investors as the government reviews priority medical device categories with high import dependence. Companies entering the sector should assess incentive eligibility, procurement policy, MedTech park infrastructure, regulatory requirements, supplier depth, and export readiness.

India wants to reduce import dependence in high value medical technology (MedTech) segments while building a stronger domestic manufacturing and export ecosystem.

Policymakers are preparing a localization push for technically complex medical devices, creating new opportunities for manufacturers, component suppliers, healthcare technology firms, and foreign investors.

The government is reportedly reviewing 8–10 priority medical device categories where domestic production can be accelerated. These include MRI systems and components, pacemakers, continuous glucose monitoring systems, advanced ultrasound equipment, CT and X-ray components, ICU beds, high-end diagnostic analysers, and related reagents and ancillaries.

Why the opportunity matters now

India’s medical device market remains highly import-dependent, especially in advanced equipment and precision components.

Priority MedTech segments under review

The strongest opportunities in India are likely to emerge in medtech categories with high import dependence and where local production can reduce cost, improve serviceability, and strengthen healthcare supply chains.

India’s medical device market is entering a more strategic phase. The opportunity is no longer limited to demand growth, but to building the manufacturing, component, testing, and service capabilities needed to reduce import dependence in high-value segments. – Ankur Munjal, Country Director, Dezan Shira & Associates India

What policy support could include

Per reports, the government is evaluating support measures aimed at reducing dependence on imported medical technologies.

Potential measures include tariff review, component indigenization, public procurement incentives, R&D support, targeted subsidies, GST rationalization, higher export incentives, and extension of the existing PLI scheme or a new MedTech PLI program.

For investors, this means the commercial case should not be assessed only on current market demand. It should also factor in possible policy support, procurement preferences, localization incentives, and export alignment.

Procurement rules are also under review

Recent policy activity also points to a more active review of procurement conditions for medical devices. In June 2026, the Department of Pharmaceuticals invited stakeholder comments on proposed amendments to the Global Tender Enquiry (GTE) exemption list for medical devices, with submissions due by July 15, 2026. The review is relevant for domestic manufacturers, importers, healthcare institutions, and procurement agencies because changes to the list could affect how public buyers source imported medical devices and where local manufacturing may gain procurement relevance.

For manufacturers and investors, the GTE review reinforces the need to track procurement policy alongside incentives, tariffs, and localization targets.

Where the commercial opportunity is strongest

India’s MedTech localization push creates opportunities across the value chain, not just in device assembly.

The best-positioned companies will be those that combine manufacturing capability with regulatory readiness, supplier depth, servicing models, and export-standard quality systems.

Why component localization is the real growth lever

Find Business Support

Assess your India MedTech market entry strategy.

India cannot build a competitive high-value MedTech sector through final assembly alone.

Advanced devices depend on specialized components and inputs, including imaging subassemblies, sensors, semiconductors, medical-grade polymers, precision motors, alloys, X-ray tubes and detectors, ultrasound probes, electronic control systems, software platforms, and validated reagents and consumables.

This creates a strong opening for foreign component suppliers and technology firms.

MedTech parks can help reduce setup barriers

Medical device manufacturing is capital-intensive and compliance heavy. Companies often need cleanrooms, sterilization units, calibration facilities, testing labs, quality systems, and documentation infrastructure.

Specialized MedTech parks can support companies by offering:

• Shared testing and validation facilities;
• Lower upfront capital expenditure;
• Access to suppliers and technical talent;
• R&D and prototyping support;
• Regulatory and quality infrastructure;
• Faster commercialization pathways; and
• Cluster-based manufacturing advantages.

However, site selection remains critical. A location with land and incentives but weak supplier depth, testing infrastructure, talent availability, or export logistics may not support long-term competitiveness.

Software, AI, and cybersecurity are becoming part of the MedTech opportunity

India’s next MedTech growth phase will not be limited to device manufacturing. Connected devices, AI-assisted diagnostics, remote monitoring tools, imaging platforms, and software-as-a-medical-device products require strong digital compliance capabilities.

Companies will need to address:

• Software validation;
• Cybersecurity testing;
• AI model verification;
• Clinical data governance;
• Post-market monitoring;
• Device lifecycle documentation; and
• Global digital health compliance.

This creates opportunities for healthcare software firms, cybersecurity providers, validation labs, and AI quality assurance specialists.

For investors, India’s MedTech opportunity should be assessed through the full value chain. The strongest projects will be those that combine product-market fit with local sourcing, certification capacity, skilled talent, and export readiness. – Ankur Munjal, Country Director, Dezan Shira & Associates India

What investors should assess before entering India’s MedTech sector

Businesses should evaluate India’s MedTech opportunity through a value chain lens.

How businesses can prepare

Companies planning to enter or expand in India’s MedTech sector should begin with a practical market entry and localization assessment. Dezan Shira & Associates can support businesses by helping them:

• Map product lines against India’s high-import medical device categories;
• Assess whether manufacturing, component supply, or contract production is the right entry model;
• Review potential incentive eligibility;
• Evaluate MedTech parks and industrial clusters;
• Identify testing, certification, and quality requirements;
• Assess software, cybersecurity, and AI compliance needs;
• Develop a servicing and spare parts strategy; and
• Determine whether India can support regional export plans.

Companies that align early with India’s MedTech localization priorities will be better positioned to capture manufacturing, supplier, servicing, and export opportunities as policy support evolves.

Entering or expanding in India requires careful assessment of market conditions, regulatory frameworks, and sector competitiveness. Business intelligence insights help companies evaluate opportunities, benchmark competitors, and align investment strategies with India’s evolving economic landscape.

Koushan Das

Manager

Talk to an expert at India@dezshira.com

Or request a consultation at +91 0124 4001785 ext. 202

• Previous Article India’s July 2026 Income Tax Calendar: New ITR, TDS & TCS Forms You Must Know
• Next Article